We’re delighted to be in Minneapolis for the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting. From May 16th-18th, we’ll be ready to connect, collaborate, and showcase our Callavid® vaginal drug delivery innovation at the largest meeting of obstetricians and gynecologists in the US. This is an exciting opportunity to discuss …

We’re delighted to welcome Amy Coulson to CLCC in advance of starting her Ph.D. journey at Queen Mary University of London. Over the next 4 years she’ll be working with our team and QMUL’s Centre for Doctoral Training in Next Generation Organ on a Chip Technology (COaCT) to develop a vaginal organ-on-a-chip to grasp successful …

We believe that true success in business must be measured not just by commercial milestones, but by the positive impact we create. To us, being a B Corp is more than a certification – it’s a daily commitment to balancing people, planet, profit, and purpose. B Lab’s rigorous standards provide a clear framework for accountability …

A promising new study published in the BJOG Journal (British Journal of Obstetrics and Gynaecology / Royal College of Obstetricians and Gynaecologists) explores the use of vaginal progesterone for couples facing unexplained infertility. 👀 Could this pave the way for broader use of vaginal progesterone prior to IVF —especially for those who can’t access IVF …

🎧 We loved this recent BBC Radio interview with Professor Siobhan Quenby MBE, who is leading the clinical trial of our progesterone-loaded Callavid at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust. 🔗 Listen to the clip: https://lnkd.in/e9GkFDaD Professor Quenby shares how our pioneering drug delivery technology could support women globally experiencing threatened miscarriage — …

Grateful to BBC News for spotlighting our work on progesterone-Callavid®, our novel drug delivery technology aimed at helping treat threatened miscarriage. “The current delivery method can leak and cost the [British economy and] NHS up to £236m per year, health economists say. University Hospitals Coventry and Warwickshire (UHCW) NHS Trust is leading the trial and …

We are excited to welcome Lia Mae Pellegrini as a Product Development Engineering Intern! Lia Mae holds a First Class Honours Master’s in Product Design Engineering from Queen’s University Belfast, where in her final year of university she reached the finals of both the Co-Founders programme run by the Northern Ireland tech hub Catalyst and …

Trust leads clinical trial of pioneering product to tackle threatened miscarriage 8 April 2025 Experts from University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are to lead a clinical trial of a novel device aimed at addressing threatened miscarriage. More than 150,000 women a year in the UK could be helped by Callavid® which is designed …

Our colleague Elham Shirani  will be at the second Microbes in Women’s Health Congress in Amsterdam on 9-10 April. 🇳🇱 We’re excited to meet with existing and new partners for 2 days of talks, panels and networking.  Our user convenient Callavid® drug delivery platform will help provide effective colonisation and epithelial adherence of live biotherapeutics …

[From NIHR: National Institute for Health and Care Research] We have awarded £1 million in funding to a first of its kind technology that’s being trialled to address threatened miscarriage. Currently, over 150,000 women in the UK experience threatened miscarriage a year. If approved, the device would become the world’s first drug-device combination to treat …